专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明申请

US20110159044A1 SILVER ION DELIVERY PLATFORM 有权
标题翻译：银离子交付平台
公开(公告)号：US20110159044A1
公开(公告)日：2011-06-30
申请号：US12737859
申请日：2009-09-01
申请人： Robert S. Neuwirth
发明人： Robert S. Neuwirth
IPC分类号： A61K9/00 , A61K33/38 , A61K31/28 , A61P15/00 , A61P7/00
CPC分类号： A61K33/38 , A61K9/0039 , A61K9/0092 , A61K47/32 , A61K47/36
摘要： The present invention pertains to silver ion bearing carriers useful in treating monorrhagia of a mammalian uterus, comprising a physiologically inert, flexible earner, e.g., a coil, bearing a tissue cauterizing amount of a silver ion. Silver ions are delivered to the endometrium and cause necrosis of the endometrial tissue. The silver ions remaining within the uterine cavity can then be neutralized with a sodium chloride solution delivered to the uterus e.g., by catheter, and the carrier recovered from the uterus.
摘要翻译：本发明涉及可用于治疗哺乳动物子宫的出血的银离子负载载体，其包含生理上惰性的柔性载体，例如具有组织烧灼量的银离子的线圈。银离子被递送到子宫内膜并引起子宫内膜组织的坏死。残留在子宫腔内的银离子然后可以用例如通过导管递送到子宫的氯化钠溶液中和，并且从子宫回收载体。

92. 发明授权

US07906554B2 Combination chemotherapy compositions and methods 失效
标题翻译：组合化疗组合物和方法
公开(公告)号：US07906554B2
公开(公告)日：2011-03-15
申请号：US10530176
申请日：2003-10-02
申请人： Graham Edmund Kelly
发明人： Graham Edmund Kelly
IPC分类号： A61K33/24 , A61K31/55 , A61K31/35 , A61K31/28 , A01N43/54 , A01N43/02 , A01N55/02
CPC分类号： C07F15/0093 , A61K31/12 , A61K31/282 , A61K31/337 , A61K31/352 , A61K31/353 , A61K31/555 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： This invention relates to combination therapies involving anticancer chemotherapeutic agents and isoflavones or analogues thereof. The invention further relates to compounds, methods and therapeutic uses involving, containing, comprising, including and/or for preparing platinum-isoflavonoid complexes suitable for use in the combination therapies of the invention.
摘要翻译：本发明涉及涉及抗癌化学治疗剂和异黄酮或其类似物的组合疗法。本发明还涉及涉及适用于本发明联合治疗的铂 - 异黄酮类复合物的化合物，方法和治疗用途，所述化合物，方法和治疗用途涉及，含有，包含，包含和/或制备铂 - 异黄酮型复合物。

93. 发明申请

US20110054019A1 Cancer Starvation Therapy 审中-公开
标题翻译：癌症饥饿治疗
公开(公告)号：US20110054019A1
公开(公告)日：2011-03-03
申请号：US12552116
申请日：2009-09-01
申请人： Pedro Anastacio Serrano-Ojeda
发明人： Pedro Anastacio Serrano-Ojeda
IPC分类号： A61K31/32 , C07F15/00 , C07F9/00 , C07F11/00 , C07F1/08 , C07F15/02 , C07F15/06 , C07F7/22 , C07F5/00 , C07F7/00 , A61K31/28 , A61K31/30 , A61K31/295 , A61K31/29 , A61P35/00
摘要： The present invention is a glutamine analogue which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
摘要翻译：本发明是进入线粒体并随后暴露于电离辐射的谷氨酰胺类似物。当暴露于电离辐射时，本发明损害线粒体（以及其他）亚结构，例如mtDNA，外膜，内膜，嵴，核糖体等，并导致这种线粒体的有效破坏。没有线粒体的肿瘤发生细胞不能产生他们需要存活和复制的能量，有效地使他们的能量饥饿并导致其破坏。

94. 发明授权

US07893289B2 Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids 有权
标题翻译：硫代钼酸和硫代酸的金刚烷胺和奈拉美辛盐
公开(公告)号：US07893289B2
公开(公告)日：2011-02-22
申请号：US11992991
申请日：2008-02-21
申请人： Om P. Goel
发明人： Om P. Goel
IPC分类号： C07F11/00 , A61K31/28
CPC分类号： C07C211/63 , C07C2601/14 , C07C2603/74
摘要： This invention concerns adamantanamines (e.g. memantine, amantadine, and rimantadine) and neramexane salts of thiomolybdic and thiotungstic acids, including their preparation and pharmaceutical compositions, as dual acting drugs. These salts are used to treat or potentially arrest the neurodegenerative pathophysiology, clinical signs and symptoms of dementia of the Alzheimer's type, Parkinson's, Huntington's, AIDS-related dementia and Schizophrenia and its cognitive deficits. Additional uses of these derivatives include antiviral activity. The novel compositions of the present invention appear particularly useful in enhancing the therapeutic benefits of copper-sequestering tetrathiomolybdates in treating elevated copper-induced toxicities in neurologically presenting Wilson's disease, and in treating diseases of the inflammatory etiology and abnormal copper biochemistry, such as tumor angiogenesis, liver cirrhosis, hepatitis, pulmonary fibrosis and other fibrotic diseases, cardiovascular disease, cerebral ischemia, renal anemia, rheumatoid arthritis, diabetes, obesity, gastrointestinal disorders, and eye diseases such as glaucoma, proliferative diabetic retinopathy, and age related macular degeneration. These compounds have excellent stability and aqueous solubility for good oral bioavailability.
摘要翻译：本发明涉及硫代钼酸和硫代酸的金刚烷胺（例如美金刚，金刚烷胺和金刚乙胺）和奈拉美生盐，包括它们的制备和药物组合物，作为双作用药物。这些盐用于治疗或潜在地阻止阿尔茨海默氏症，帕金森氏症，亨廷顿舞蹈症，艾滋病相关性痴呆和精神分裂症及其认知缺陷的神经变性病理生理学，临床症状和痴呆症状。这些衍生物的其它用途包括抗病毒活性。本发明的新型组合物特别可用于增强铜螯合四硫钼酸盐在治疗神经性呈现威尔逊氏症中升高的铜诱导毒性以及治疗炎性病因学和异常铜生物化学疾病如肿瘤血管生成中的治疗益处，肝硬化，肝炎，肺纤维化等纤维化疾病，心血管疾病，脑缺血，肾性贫血，类风湿性关节炎，糖尿病，肥胖症，胃肠道疾病和眼部疾病如青光眼，增殖性糖尿病性视网膜病变和年龄相关性黄斑变性。这些化合物具有优异的稳定性和水溶性，以获得良好的口服生物利用度。

95. 发明授权

US07888523B2 Preparation of platinum(II) complexes 失效
标题翻译：铂（II）配合物的制备
公开(公告)号：US07888523B2
公开(公告)日：2011-02-15
申请号：US12508466
申请日：2009-07-23
申请人： Jan Gysbert Hermanus Du Preez
发明人： Jan Gysbert Hermanus Du Preez
IPC分类号： C07F15/00 , A61K31/28
CPC分类号： C07F15/0093
摘要： This invention relates to a method for the preparation of a platinum(II) complex containing a neutral bidentate ligand, such as oxaliplatin. The method includes the step of reacting a halogenoplatinum complex containing a neutral bidentate ligand with an oxalate salt in a solvent, wherein more than 1 g/L of the oxalate salt is soluble in the solvent. The invention also relates to new platinum(II) complexes.
摘要翻译：本发明涉及一种制备含有中性二齿配体如奥沙利铂的铂（II）络合物的方法。该方法包括使含有中性二齿配体的卤代铂络合物与草酸盐在溶剂中反应的步骤，其中大于1g / L的草酸盐可溶于溶剂。本发明还涉及新的铂（II）络合物。

96. 发明申请

US20100316628A1 AGENTS AND METHODS FOR TREATING RESPIRATORY DISORDERS 审中-公开
标题翻译：用于治疗呼吸道疾病的药剂和方法
公开(公告)号：US20100316628A1
公开(公告)日：2010-12-16
申请号：US12634432
申请日：2009-12-09
申请人： Sylvie Breton , Dennis Brown , Wai Chi Shum , Nicolas Da Silva
发明人： Sylvie Breton , Dennis Brown , Wai Chi Shum , Nicolas Da Silva
IPC分类号： A61K39/395 , A61P11/00 , A61P37/08 , A61P11/06 , A61K38/02 , A61K38/16 , A61K31/7088 , A61K31/713 , A61K31/4166 , A61K31/416 , A61K31/555 , A61K31/28
CPC分类号： A61K31/28 , A61K9/0073 , A61K31/416 , A61K31/4166 , A61K31/555 , A61K31/7088 , A61K31/713
摘要： The present invention relates to a novel method of preventing and/or treating respiratory disorders and respiratory-related complications in a subject by inhibiting the release of nitric oxide from basal cells in the respiratory tract.
摘要翻译：本发明涉及一种通过抑制一氧化氮从呼吸道基细胞中释放而预防和/或治疗受试者呼吸系统疾病和呼吸相关并发症的新方法。

97. 发明申请

US20100267825A1 TREATMENT OF SKIN DAMAGE 审中-公开
标题翻译：治疗皮肤损伤
公开(公告)号：US20100267825A1
公开(公告)日：2010-10-21
申请号：US12759970
申请日：2010-04-14
申请人： Bernard Malfroy-Camine
发明人： Bernard Malfroy-Camine
IPC分类号： A61K31/28 , C12Q1/02 , C12M1/34 , A61P17/00
CPC分类号： A61K31/28 , G01N33/5091 , G01N2800/20 , G01N2800/40
摘要： Methods and apparatus are disclosed for diagnosing and treating oxidative skin damage in a subject. The therapeutic method can comprise: (i) diagnosing a level of oxidative skin damage in a sample comprising stratum corneum of the subject; and (ii) recommending a therapeutic regime for treatment of oxidative skin damage in the subject, wherein said recommendation comprises a recommendation to administer a pharmaceutical formulation comprising an amount of one or more specific synthetic SOD/catalase mimetics sufficient to treat the level of oxidative skin damage of the subject as diagnosed. The diagnostic method can further include obtaining a sample from the stratum corneum of a subject; measuring the level of at least one oxidized substance in the sample; and comparing a detected level of the oxidized substance with a standard, whereby an elevated level of the oxidized substance is indicative of skin damage.
摘要翻译：公开了用于诊断和治疗受试者的氧化性皮肤损伤的方法和装置。治疗方法可以包括：（i）诊断包含受试者的角质层的样品中的氧化皮肤损伤水平; 和（ii）建议用于治疗受试者的氧化性皮肤损伤的治疗方案，其中所述建议包括施用药物制剂的建议，其包含一定量的足以治疗氧化皮肤水平的一种或多种特异性合成SOD /过氧化氢酶模拟物被诊断的受试者的损伤。诊断方法还可以包括从受试者的角质层获得样品; 测量样品中至少一种氧化物质的含量; 并将氧化物质的检测水平与标准物进行比较，由此升高的氧化物质水平表示皮肤损伤。

98. 发明授权

US07803407B2 Disinfectant and method of making 有权
标题翻译：消毒剂和制造方法
公开(公告)号：US07803407B2
公开(公告)日：2010-09-28
申请号：US10600006
申请日：2003-06-19
申请人： Andrew B. Arata
发明人： Andrew B. Arata
IPC分类号： A01N59/16 , A01N55/02 , A01N37/04 , A61K33/38 , A61K31/28 , A61K31/191
CPC分类号： A61L2/238 , A01N37/36 , A01N59/16 , A61L2/18 , A61L2202/11 , C02F1/4606 , C11D3/168 , C11D3/48 , C11D7/265 , Y10S424/06 , A01N31/02 , A01N25/02 , A01N2300/00
摘要： A non-toxic environmentally friendly aqueous disinfectant is disclosed for specific use as prevention against contamination by potentially pathogenic bacteria and virus. The aqueous disinfectant is formulated by electrolytically generating silver ions in water in combination with a citric acid. The aqueous disinfectant may include a suitable alcohol and/or a detergent. The aqueous disinfectant has been shown to be very effective at eliminating standard indicator organisms such as staphylococcus aureus, salmonella cholerasuis and pseudomonas aeruginosa.
摘要翻译：公开了一种无毒的环保型水性消毒剂用于特定用途，以防止潜在致病细菌和病毒的污染。水消毒剂通过与柠檬酸组合在水中电解产生银离子来配制。水性消毒剂可以包括合适的醇和/或洗涤剂。已经显示水消毒剂在消除标准指示生物如金黄色葡萄球菌，霍乱沙门氏菌和铜绿假单胞菌方面非常有效。

99. 发明申请

US20100209431A1 METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME 失效
标题翻译：金属三角胶体化合物及其使用方法
公开(公告)号：US20100209431A1
公开(公告)日：2010-08-19
申请号：US12596138
申请日：2008-04-04
申请人： Shazib Pervaiz , Sanjiv Kumar Yadav
发明人： Shazib Pervaiz , Sanjiv Kumar Yadav
IPC分类号： C07F15/00 , C12N5/00 , A61K31/28 , A61K31/65 , A61K33/36 , A61K31/175 , A61K38/18 , A61K31/66 , A61K39/395 , A61P35/04
CPC分类号： A61K31/28 , A61K31/32 , A61K45/06 , C07F15/0026
摘要： The present invention relates to a metal triangulo compound. Provided is also a method of inducing apoptosis in a cell that comprises administering the metal triangulo compound. Provided is also a method of preventing carcinogenesis in a cell that comprises administering the metal triangulo compound.
摘要翻译：本发明涉及金属三联体化合物。还提供了诱导细胞凋亡的方法，其包括施用金属三联化合物。本发明还提供一种预防细胞致癌作用的方法，其包括施用金属三联化合物。

100. 发明授权

US07767709B2 Pharmaceutical composition for oral administration 有权
标题翻译：用于口服给药的药物组合物
公开(公告)号：US07767709B2
公开(公告)日：2010-08-03
申请号：US12305337
申请日：2007-06-20
申请人： Ales Franc , Petr Sova
发明人： Ales Franc , Petr Sova
IPC分类号： A61K31/28
CPC分类号： A61K47/14 , A61K9/10 , A61K9/4858 , A61K31/282 , A61K33/24
摘要： An oral pharmaceutical composition characterized in that it consists of a suspension of a platinum complex of general formula I, wherein A and A′ independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B′ independently of one another are a halogen atom or a hydroxy group or are an —O—C(O)—R or an —O—C(O)—R′ group wherein R and R′ independently of one another are hydrogen atom, an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group which groups contain 1 to 10 carbon atoms, or functional derivatives of these groups, X and X′ independently of one another are a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X and X′ together form a dicarboxylate group containing 2 to 20 carbon atoms, in at least one pharmaceutically acceptable vegetable, animal, mineral, synthetic or semisynthetic oil and/or in at least one pharmaceutically acceptable vegetable, animal, mineral, synthetic or semisynthetic oily substance, in which suspension the content of the platinum complex of general formula I is 0.5 to 50% by weight based on the total weight of the composition, and which suspension optionally contains at least one pharmaceutically acceptable excipient.
摘要翻译：一种口服药物组合物，其特征在于其由通式I的铂络合物的悬浮液组成，其中A和A'彼此独立地为NH 3基团或含有1至18个碳原子的氨基或二氨基，B和B “彼此独立的是卤素原子或羟基，或者是-O-C（O）-R或-O-C（O）-R'基团，其中R和R'彼此独立地是氢原子，含有1〜10个碳原子的烷基，烯基，芳基，芳烷基，烷基氨基或烷氧基，或这些基团的官能衍生物，X和X'彼此独立地是卤素原子或含有1至20个碳原子的单羧酸盐基团碳原子或X和X'在至少一种药学上可接受的植物，动物，矿物，合成或半合成油和/或至少一种药学上可接受的植物，动物，矿物质中一起形成含有2至20个碳原子的二羧酸酯基，合成o r半合成油状物质，其中通式I的铂络合物的含量相对于组合物的总重量为0.5〜50重量％，该悬浮液任选地含有至少一种药学上可接受的赋形剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式